IL236088A0 - n-Alkyltriazole compounds as lpar antagonists - Google Patents

n-Alkyltriazole compounds as lpar antagonists

Info

Publication number
IL236088A0
IL236088A0 IL236088A IL23608814A IL236088A0 IL 236088 A0 IL236088 A0 IL 236088A0 IL 236088 A IL236088 A IL 236088A IL 23608814 A IL23608814 A IL 23608814A IL 236088 A0 IL236088 A0 IL 236088A0
Authority
IL
Israel
Prior art keywords
alkyltriazole
compounds
lpar antagonists
lpar
antagonists
Prior art date
Application number
IL236088A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL236088(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL236088A0 publication Critical patent/IL236088A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL236088A 2012-06-20 2014-12-04 n-Alkyltriazole compounds as lpar antagonists IL236088A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661961P 2012-06-20 2012-06-20
PCT/EP2013/062461 WO2013189864A1 (en) 2012-06-20 2013-06-17 N-alkyltriazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
IL236088A0 true IL236088A0 (en) 2015-02-01

Family

ID=48628667

Family Applications (1)

Application Number Title Priority Date Filing Date
IL236088A IL236088A0 (en) 2012-06-20 2014-12-04 n-Alkyltriazole compounds as lpar antagonists

Country Status (22)

Country Link
US (1) US9321738B2 (OSRAM)
EP (1) EP2864300A1 (OSRAM)
JP (1) JP2015520202A (OSRAM)
KR (1) KR20150021057A (OSRAM)
CN (1) CN104411692A (OSRAM)
AU (1) AU2013279512A1 (OSRAM)
BR (1) BR112014030685A2 (OSRAM)
CA (1) CA2869541A1 (OSRAM)
CL (1) CL2014003243A1 (OSRAM)
CO (1) CO7131358A2 (OSRAM)
CR (1) CR20140525A (OSRAM)
EA (1) EA201492285A1 (OSRAM)
HK (1) HK1206342A1 (OSRAM)
IL (1) IL236088A0 (OSRAM)
IN (1) IN2014DN09348A (OSRAM)
MA (1) MA37764A1 (OSRAM)
MX (1) MX2014014710A (OSRAM)
PE (1) PE20142448A1 (OSRAM)
PH (1) PH12014502789A1 (OSRAM)
SG (1) SG11201407220YA (OSRAM)
UA (1) UA109868C2 (OSRAM)
WO (1) WO2013189864A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2014011555A (en) 2011-08-15 2014-08-28 Intermune Inc Lysophosphatidic acid receptor antagonists
SG11201407228PA (en) * 2012-06-20 2014-12-30 Hoffmann La Roche N-aryltriazole compounds as lpar antagonists
KR102090231B1 (ko) 2013-03-15 2020-03-17 에피젠 바이오싸이언시즈, 아이엔씨. 질환의 치료에 유용한 헤테로환식 화합물
CN106458964B (zh) 2014-06-27 2019-11-22 宇部兴产株式会社 卤素取代杂环化合物的盐
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2019126085A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
US11447475B2 (en) 2017-12-19 2022-09-20 Bristol-Myers Squibb Company Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
EP3728223B1 (en) * 2017-12-19 2022-12-28 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as lpa antagonists
CN112074515B (zh) 2017-12-19 2025-01-10 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑唑类
PE20210655A1 (es) 2017-12-19 2021-03-31 Bristol Myers Squibb Co Carbamoil ciclohexil acidos ligados a n de triazol como antagonistas de lpa
EP3728240B1 (en) * 2017-12-19 2022-06-29 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
JP7299892B2 (ja) * 2017-12-19 2023-06-28 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン
EP3728209A1 (en) * 2017-12-19 2020-10-28 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as lpa antagonists
AR113965A1 (es) * 2017-12-19 2020-07-01 Bristol Myers Squibb Co Triazol azoles ciclohexil ácidos como antagonistas de lpa
JP7202383B2 (ja) 2017-12-19 2023-01-11 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのピラゾールo-架橋カルバモイルシクロヘキシル酸
US11352345B2 (en) 2017-12-19 2022-06-07 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as LPA antagonists
WO2019133770A2 (en) * 2017-12-29 2019-07-04 Biomarin Pharmaceutical Inc. Glycolate oxidase inhibitors for the treatment of disease
WO2020060916A1 (en) * 2018-09-18 2020-03-26 Bristol-Myers Squibb Company Cycloheptyl acids as lpa antagonists
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN113366000A (zh) * 2018-09-18 2021-09-07 百时美施贵宝公司 作为lpa拮抗剂的氧杂双环酸
CN114728168B (zh) * 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
CN115867556B (zh) 2020-06-03 2025-05-06 吉利德科学公司 Lpa受体拮抗剂及其用途
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
JP7701473B2 (ja) 2021-05-11 2025-07-01 ギリアード サイエンシーズ, インコーポレイテッド Lpa受容体アンタゴニスト及びそれらの使用
JP7691522B2 (ja) * 2021-05-13 2025-06-11 ギリアード サイエンシーズ, インコーポレイテッド Lpa受容体アンタゴニスト及びそれらの使用
EP4444707A1 (en) 2021-12-08 2024-10-16 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
AR128613A1 (es) 2022-02-25 2024-05-29 Lhotse Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
JP2014508111A (ja) 2010-12-07 2014-04-03 アミラ ファーマシューティカルス,インコーポレーテッド リゾフォスファチジン酸受容体アンタゴニスト、その線維症の治療における使用
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
SG2014011555A (en) * 2011-08-15 2014-08-28 Intermune Inc Lysophosphatidic acid receptor antagonists

Also Published As

Publication number Publication date
CN104411692A (zh) 2015-03-11
CL2014003243A1 (es) 2015-03-20
UA109868C2 (ru) 2015-10-12
CA2869541A1 (en) 2013-12-27
SG11201407220YA (en) 2014-12-30
AU2013279512A1 (en) 2014-10-16
JP2015520202A (ja) 2015-07-16
PH12014502789A1 (en) 2015-02-09
IN2014DN09348A (OSRAM) 2015-07-17
MX2014014710A (es) 2015-03-04
HK1206342A1 (en) 2016-01-08
WO2013189864A1 (en) 2013-12-27
US20150133511A1 (en) 2015-05-14
EP2864300A1 (en) 2015-04-29
CO7131358A2 (es) 2014-12-01
US9321738B2 (en) 2016-04-26
EA201492285A1 (ru) 2015-04-30
PE20142448A1 (es) 2015-01-28
KR20150021057A (ko) 2015-02-27
BR112014030685A2 (pt) 2017-06-27
MA37764A1 (fr) 2016-01-29
CR20140525A (es) 2015-01-12

Similar Documents

Publication Publication Date Title
IL236087A0 (en) n–aryltriazole compounds as lpar antagonists
IL236088A0 (en) n-Alkyltriazole compounds as lpar antagonists
SG11201406274VA (en) Novel compounds
GB201207406D0 (en) Novel compounds
IL239447A0 (en) new compounds
IL238800A0 (en) new compounds
GB201212871D0 (en) Novel compounds
IL236091A0 (en) Pyrazole compounds are converted as lpar antagonists
GB201209986D0 (en) Novel compounds
IL280595A (en) new compounds
GB201222711D0 (en) Novel compounds
GB201207392D0 (en) Novel compounds
GB201209670D0 (en) Novel compounds
GB201212816D0 (en) Novel compounds
GB201222433D0 (en) Novel compounds
GB201222419D0 (en) Novel compounds
GB201222430D0 (en) Novel compounds
GB201222435D0 (en) Novel compounds
GB201222393D0 (en) Novel compounds
GB201219554D0 (en) Novel compounds
GB201219472D0 (en) Novel compounds
GB201217387D0 (en) Novel compounds
GB201216548D0 (en) Novel compounds
GB201216551D0 (en) Novel compounds
GB201213023D0 (en) Novel compounds